Screener
Tarsus Pharmaceuticals, Inc. TARS Unrecognized Tax Benefits
Unrecognized Tax Benefits at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefits.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s unrecognized tax benefits?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unrecognized tax benefits of $4.3M in Q2 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unrecognized tax benefits?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s unrecognized tax benefits has grown at a 54.5% compound annual growth rate (CAGR), from $488K to $4.3M.
- What does unrecognized tax benefits mean?
- This represents the amount of tax benefits from uncertain tax positions that have not been recognized in the financial statements because they do not meet the 'more-likely-than-not' threshold. It reflects the company's exposure to potential tax audits and disputes with tax authorities. This is a key indicator of tax-related legal and financial risk.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unrecognized tax benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude